Endocrine And Reproductive

Front 1

Insulin FAST

Back 1

Lispro and Aspart (Lance Armstrong) most quickly increase activity of TK

Front 2

Insulin SLOW

Back 2

Detemir and Glargine, less variability of serum insulin levels

Front 3

Insulin MOA

Back 3

2nd messenger is Tyrosine Kinase

Front 4

Insulin USE

Back 4

Diabetes

Front 5

Biguinides MOA

Back 5

Increase glycolysis and decrease gluconeogenesis

Front 6

Biguinides

Back 6

Metformin

Front 7

Metformin CONTRAINDICATION

Back 7

with IV contrast dye

Front 8

Alpha-glucosidase inhibitors

Back 8

Ascarbose and Miglitol

Front 9

Alpha-glucosidase inhibitors USE

Back 9

Post Prandial (after you eat) Glycemic Control

Front 10

Alpha-glucosidase inhibitors MOA

Back 10

Inhibit glucose absorption in small intestine brush border where enzyme is located, glucose is excreted with feces

Front 11

Alpha-glucosidase inhibitors SE

Back 11

Osmotic Diarrhea (Ass-carbose) glucose is followed by water

Front 12

Thiazolidinediones/Glitazones

Back 12

Proglitazone and Rosiglitazone

Front 13

Thiazolidinediones/Glitazones MOA

Back 13

Bind to PPAR to increase insulin receptor sensitivity, increase transcription of receptor

Front 14

Thiazolidinediones/Glitazones SE

Back 14

Increase levels of adiponectin, obesity

Front 15

Sulfonylureas MOA

Back 15

Close Potassium channels, potassium stays in cell, depolarization of islet beta cells, increase Ca2+ influx, increase insulin release, increase C-peptide levels

Front 16

Sulfonylureas 1ST GEN

Back 16

Tolbutamide, Chlorpropamide

Front 17

Sulfonylureas 2ND GEN

Back 17

Glyburide, Glumepiride, Glipizide

Front 18

Sulfonylureas SE

Back 18

Hypoglycemia (even more in 2nd gen)

Front 19

Somoji effect

Back 19

Early morning hypoglycemia leading to reactive hyperglycemia, decrease night time insulin dose

Front 20

Dawn Effect

Back 20

physiological hyperglycemia due to early morning stress hormones

Front 21

Propylthiouricil and Methamazol MOA

Back 21

Blocks peroxidase and 5' deiodinase (takes T4 to T3 peropherally)

Front 22

Propylthiouricil and Methamazol SE

Back 22

Skin rash, aplastic anemia, hepatotoxicity (PTU)

Front 23

Propylthiouricil and Methamazol USE

Back 23

Hyperthyroidism

Front 24

Propanolol MOA

Back 24

Decreases peripheral conversion of T4 to T3 (5' deiodinase

Front 25

Triiodothyronine and Levothyroxine MOA

Back 25

Thyroxine replacement

Front 26

Triiodothyronine and Levothyroxine USE

Back 26

Hypothyroidism and Myxedema

Front 27

Triiodothyronine and Levothyroxine SE

Back 27

Tachycardia, heat intolerance, tremor, arrhytmia

Front 28

Demoxycycline USE

Back 28

SIADH, helps expel the volume accumulated

Front 29

Demoxycycline MOA

Back 29

ADH antagonist

Front 30

Demoxycycline SE

Back 30

Nephrogenic Diabetes Insipidus (not responding to ADH), photosensitivity, tooth and bone abnormalities

Front 31

GH USE

Back 31

GH deficiency and Turners syndrome

Front 32

Somatostatin

Back 32

Octreotide

Front 33

Somatostatin USE

Back 33

Esophageal Varices (vein dilation and hematemesis), Acromegaly (antagonize GH), Carcinoid, Gastrinoma (decrease motility), Glucagonoma

Front 34

Desmopressin (ADH) USE

Back 34

Central diabetes Insipidus or neurogenic (not making ADH)

Front 35

Leuprolide MOA

Back 35

GNRH analog, works as an agonist if administered in a pulsatile fashion

Front 36

Leuprolide USE

Back 36

Pulsatile: infertility, Continuous: Prostate cancer, uterine fibroids and precocious puberty

Front 37

Testosterone and Methyltestosterone MOA

Back 37

Androgen receptor agonists, inhibit LH to produce less Testosterone

Front 38

Testosterone and Methyltestosterone SE

Back 38

Masculinization (female), gonadal atrophy, Increase LDL, Decrease HDL, Early epiphyseal plate closure

Front 39

Testosterone and Methyltestosterone USE

Back 39

Hypogonadism, Anabolism in burn patients

Front 40

Finasteride MOA

Back 40

5 alpha reductase inhibitor which is responsible for testosterone conversion to DHT

Front 41

Finasteride USE

Back 41

BPH and Male pattern baldness

Front 42

Ketoconazole MOA

Back 42

inhibits 17,20 desmolase, inhibit steroid synthesis

Front 43

Ketoconazole USE

Back 43

PCOS

Front 44

Flutamide MOA

Back 44

competetive irreversible inhibition at testosterone receptor

Front 45

Flutamide USE

Back 45

Prostate cancer

Front 46

Spironolactone MOA

Back 46

Aldosterone antagonist inhibits steroid synthesis

Front 47

Spironolactone USE

Back 47

PCOS

Front 48

Estrogens

Back 48

Ethilyn Estradiol, DES, Mistranol

Front 49

Estrogens MOA

Back 49

Bind estrogen receptors

Front 50

Estrogens USE

Back 50

hypogonadism, ovarian failure, postmenopausal hormone replacement therapy, androgen dependent prostate cancer

Front 51

Estrogens SE

Back 51

Increase risk of endometrial cancer, post menopausal bleeding, increase risk thrombus

Front 52

Estrogens CONTRAINDICATION

Back 52

Estrogen Receptor positive breast cancer, DVT

Front 53

SERM

Back 53

Clomiphene, Tamoxifen and Raloxifen

Front 54

Clomiphene MOA

Back 54

partial estrogen receptor agonist

Front 55

Clomiphene SE

Back 55

hot flashes, ovarian enlargement, multiple simultaneous pregnancies

Front 56

Clomiphene USE

Back 56

infertility and PCOS

Front 57

Oxytocin USE

Back 57

Stimulate labor, Uterine contractions, lactation, control uterine hemorrhage

Front 58

Tamoxifen and Raloxifen MOA

Back 58

Antagonist at breast and agonist at bone

Front 59

Tamoxifen and Raloxifen USE

Back 59

prevent recurrent ER-positive breast cancer, osteoporosis

Front 60

Tamoxifen SE

Back 60

Endometrial Cancer but not raloxifen

Front 61

Anastrozole and Exemestane MOA

Back 61

Aromatase inhibitors

Front 62

Anastrozole and Exemestane USE

Back 62

post menopausal patients with breast cancer

Front 63

Progestins MOA

Back 63

bind progesterone receptors, increase endometrial vascularization

Front 64

Progestins USE

Back 64

Oral contraceptive, endometrial cancer, abnormal uterine bleeding

Front 65

Mifepristone MOA

Back 65

competetive inhibitor of progesterone receptors, irreversible

Front 66

Mifepristone SE

Back 66

heavy bleeding, nausea, vomit, anorexia, abdominal pain

Front 67

Mifepristone USE

Back 67

Abortifacent, morning after pill and taken with misoprostil (PGE1)

Front 68

Terbutaline and Ritodrine MOA

Back 68

Beta 2 agonist, relaxes uterus

Front 69

Terbutaline and Ritodrine USE

Back 69

Reduce premature uterine contaction

Front 70

Tamsulosin MOA

Back 70

alpha-1 antagonist, inhibits smooth muscle contraction allows for urination

Front 71

Tamsulosin USE

Back 71

BPH, selective a1A,D receptor found in prostate

Front 72

Sildenafil and Verdenaful MOA

Back 72

inhibit Phosphodiesterase 5, increase cGMP, vasodilation

Front 73

Sildenafil and Verdenafil USE

Back 73

Erectile dysfunction

Front 74

Sildenafil and Verdenafil SE

Back 74

Dyspepsia, headache, flushing, impaired blue-green color vision, severe hypotension in patients taking nitrates

Front 75

Danazol MOA

Back 75

partial agonist at androgen receptors

Front 76

Danazol USE

Back 76

Endometriosis, hereditary angioedema

Front 77

Danazol SE

Back 77

weight gain, edema, hirsutism, acne, decrease HDL, Hepatotoxicity